Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).
Sicuranza A, Ferrigno I, Abruzzese E, Iurlo A, Galimberti S, Gozzini A, Luciano L, Stagno F, Russo Rossi A, Sgherza N, Cattaneo D, Zuanelli Brambilla C, Marzano C, Fava C, Mulas O, Cencini E, Santoni A, Sammartano V, Gozzetti A, Puccetti L, Bocchia M. Sicuranza A, et al. Among authors: bocchia m. Front Oncol. 2022 Feb 1;12:835563. doi: 10.3389/fonc.2022.835563. eCollection 2022. Front Oncol. 2022. PMID: 35178353 Free PMC article.
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F. Bocchia M, et al. Lancet. 2005 Feb 19-25;365(9460):657-62. doi: 10.1016/S0140-6736(05)17945-8. Lancet. 2005. PMID: 15721470 Free article. Clinical Trial.
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT, Bocchia M, Bucalossi A, Defina M, Forconi F, Gozzetti A, Lauria F. Pirrotta MT, et al. Among authors: bocchia m. Acta Haematol. 2007;118(1):7-9. doi: 10.1159/000100992. Epub 2007 Mar 26. Acta Haematol. 2007. PMID: 17389781 No abstract available.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11. Blood. 2009. PMID: 19211938 Free article. Clinical Trial.
Cutaneous myeloma and bortezomib.
Gozzetti A, Defina M, Bocchia M. Gozzetti A, et al. Among authors: bocchia m. Ann Hematol. 2009 Oct;88(10):1045. doi: 10.1007/s00277-009-0786-7. Epub 2009 Jul 14. Ann Hematol. 2009. PMID: 19597817 Free article. No abstract available.
316 results